News and Announcements
OpenDNA’s Patented Technology Reinforces the Company’s Unique Selling Proposition
- Published August 18, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OpenDNA Limited (ASX:OPN) is pleased to provide the company’s quarterly activities report and Appendix 4C for the quarter ended 30 June 2017.
KEY TAKEAWAYS:
- Key technological advances made to bolster and leverage the Company’s core artificial intelligence system.
- Updated and additions to OpenDNA’s patented technology reinforces the company’s unique selling proposition.
- Key new market sectors, including mobile phone handsets, food & beverage, luxury goods.
- Development and conversion of potential customer pipeline, with signature of additional customer agreements expected imminently.
OpenDNA’s Chief Executive Officer and MD, Jay Shah, commented on progress during the Quarter by saying:
“OpenDNA is focused on providing the most useful, relevant insights to customers regardless of the industry they operate in and we are working continually to develop ways in which to reinforce the Company’s USP for those customers. By understanding how to make our personalization and psychographic insights most useful to customers, and developing new technologies which enhance that usefulness, we are simultaneously improving our offering to current and potential customers alike. In this Quarter we have begun to see the results of the consistent efforts being made by our sales force to secure agreements with customers operating in a range of industries and we look forward to that trend continuing and increasing during the September Quarter”.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
